Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Disco Pharmaceuticals raised €36M in seed funding to advance therapies for hard-to-treat tumors, co-led by Ackermans and van Haaren and NRW.Bank.

PRIVATEDec 11, 2025•8 months ago

Amount Raised

€36 Million

Round Type

Seed

CologneBiotechnologyHealth Care

Investors

Panakes PartnersM VenturesAbb Vie VenturesSofinnova PartnersNrw.BankAckermans And Van Haaren

Description

Disco Pharmaceuticals, based in Cologne, raised €36M in seed funding. The round was co-led by Ackermans and van Haaren and NRW.Bank, with participation from existing investors. The funds will advance multiple lead antibody-drug conjugates toward IND-enabling studies. The company also appointed Mark Manfredi, Ph.D., as CEO.

Company Information

Company

Disco Pharmaceuticals

Location

Cologne, North Rhine Westphalia, Germany

About

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Disco Pharmaceuticals's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Disco Pharmaceuticals? See every signal — funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan